BOTHELL, Wash., April 26 /PRNewswire/ -- MedManage Systems Inc., a leading provider of intelligent prescription drug-sampling solutions, today announced it has received $6 million in Series C Preferred funding. The new round of financing was led by Versant Ventures, a venture capital firm that invests in early-stage healthcare companies promising to be significant, long-term market leaders. Other investors joining the round include Lilly Ventures and existing investor, Prism Venture Partners.
"The addition of Versant and Lilly Ventures, two prestigious investors, reflects the great potential MedManage's innovative solutions bring to the pharmaceutical industry," said Cecil Kost, President and CEO of MedManage Systems. "This investment will enable MedManage to continue aggressive market expansion of the company's Intelligent Sampling(TM) solutions."
About MedManage Systems
MedManage Systems offers the most comprehensive prescription drug-sampling solutions for the pharmaceutical industry. Designed to augment field sales efforts, MedManage's OmniSample(sm) Solution includes the eMedSample drug- sampling platform, alternative drug-sampling systems, physician targeting and recruitment services and marketing informatics. MedManage's solutions allow pharmaceutical companies to achieve broader, deeper and faster market penetration and provide a comprehensive sampling system through all stages of the product life cycle. Working closely with physician access partners and sample fulfillment organizations, MedManage ensures a fully integrated sampling solution.
The company's corporate headquarters are located outside Seattle, WA, with regional offices in New York, Chicago, and Boston. Additional information on MedManage can be found at http://www.medmanagesystems.com/.
MedManage Systems Inc.
CONTACT: Robert S. Nakahara, Chief Financial Officer, of MedManageSystems, +1-425-354-2202, or firstname.lastname@example.org; or Lisa Black, ofLMBPR, +1-781-631-6377, or email@example.com, for MedManage Systems